Cargando…
Experts’ Consensus on the Use of Pimecrolimus in Atopic Dermatitis in China: A TCS-Sparing Practical Approach
INTRODUCTION: Atopic dermatitis (AD) is a chronic, pruritic, inflammatory skin disease with rising prevalence. Topical corticosteroids (TCS) are recommended as first-line therapy for patients with AD in China; however, corticophobia is a widespread concern, which can manifest as noncompliance: in a...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021341/ https://www.ncbi.nlm.nih.gov/pubmed/35313362 http://dx.doi.org/10.1007/s13555-022-00696-z |
_version_ | 1784689790191403008 |
---|---|
author | Zhao, Zuotao Gao, Xing-Hua Li, Wei Wang, Hua Liang, Yunsheng Tang, Jianping Yao, Xu Zhao, Hua Luger, Thomas |
author_facet | Zhao, Zuotao Gao, Xing-Hua Li, Wei Wang, Hua Liang, Yunsheng Tang, Jianping Yao, Xu Zhao, Hua Luger, Thomas |
author_sort | Zhao, Zuotao |
collection | PubMed |
description | INTRODUCTION: Atopic dermatitis (AD) is a chronic, pruritic, inflammatory skin disease with rising prevalence. Topical corticosteroids (TCS) are recommended as first-line therapy for patients with AD in China; however, corticophobia is a widespread concern, which can manifest as noncompliance: in a previous Chinese study, almost all parents whose children had AD were very concerned about the side effects of TCS and, as a result, nearly half did not use it in the event of recurrence. We propose a TCS-sparing treatment algorithm for the management of infants, children, adolescents, and adults with mild-to-moderate AD, to guide clinical practice in China. METHODS: A panel of eight experts in AD from China and one expert from Germany formed to develop a practical algorithm for the management of mild-to-moderate AD, focusing on pimecrolimus. RESULTS: Irrespective of body location, all patients with mild AD (including acute flares) and infants with moderate AD should apply the topical calcineurin inhibitor (TCI) pimecrolimus twice daily to the affected area until symptoms disappear. For children, adolescents, and adults with moderate AD, pimecrolimus should be applied twice daily to sensitive skin areas, and a TCI (either pimecrolimus or tacrolimus) should be applied twice daily to other body locations. Short-term administration of TCS, followed by TCI twice daily, is recommended for most patients with moderate AD experiencing acute flares, regardless of lesion site. Emollients should be used regularly. CONCLUSIONS: The algorithm presented intends to simplify treatment of AD in China and guide clinical decision-making. |
format | Online Article Text |
id | pubmed-9021341 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-90213412022-05-06 Experts’ Consensus on the Use of Pimecrolimus in Atopic Dermatitis in China: A TCS-Sparing Practical Approach Zhao, Zuotao Gao, Xing-Hua Li, Wei Wang, Hua Liang, Yunsheng Tang, Jianping Yao, Xu Zhao, Hua Luger, Thomas Dermatol Ther (Heidelb) Original Research INTRODUCTION: Atopic dermatitis (AD) is a chronic, pruritic, inflammatory skin disease with rising prevalence. Topical corticosteroids (TCS) are recommended as first-line therapy for patients with AD in China; however, corticophobia is a widespread concern, which can manifest as noncompliance: in a previous Chinese study, almost all parents whose children had AD were very concerned about the side effects of TCS and, as a result, nearly half did not use it in the event of recurrence. We propose a TCS-sparing treatment algorithm for the management of infants, children, adolescents, and adults with mild-to-moderate AD, to guide clinical practice in China. METHODS: A panel of eight experts in AD from China and one expert from Germany formed to develop a practical algorithm for the management of mild-to-moderate AD, focusing on pimecrolimus. RESULTS: Irrespective of body location, all patients with mild AD (including acute flares) and infants with moderate AD should apply the topical calcineurin inhibitor (TCI) pimecrolimus twice daily to the affected area until symptoms disappear. For children, adolescents, and adults with moderate AD, pimecrolimus should be applied twice daily to sensitive skin areas, and a TCI (either pimecrolimus or tacrolimus) should be applied twice daily to other body locations. Short-term administration of TCS, followed by TCI twice daily, is recommended for most patients with moderate AD experiencing acute flares, regardless of lesion site. Emollients should be used regularly. CONCLUSIONS: The algorithm presented intends to simplify treatment of AD in China and guide clinical decision-making. Springer Healthcare 2022-03-21 /pmc/articles/PMC9021341/ /pubmed/35313362 http://dx.doi.org/10.1007/s13555-022-00696-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Zhao, Zuotao Gao, Xing-Hua Li, Wei Wang, Hua Liang, Yunsheng Tang, Jianping Yao, Xu Zhao, Hua Luger, Thomas Experts’ Consensus on the Use of Pimecrolimus in Atopic Dermatitis in China: A TCS-Sparing Practical Approach |
title | Experts’ Consensus on the Use of Pimecrolimus in Atopic Dermatitis in China: A TCS-Sparing Practical Approach |
title_full | Experts’ Consensus on the Use of Pimecrolimus in Atopic Dermatitis in China: A TCS-Sparing Practical Approach |
title_fullStr | Experts’ Consensus on the Use of Pimecrolimus in Atopic Dermatitis in China: A TCS-Sparing Practical Approach |
title_full_unstemmed | Experts’ Consensus on the Use of Pimecrolimus in Atopic Dermatitis in China: A TCS-Sparing Practical Approach |
title_short | Experts’ Consensus on the Use of Pimecrolimus in Atopic Dermatitis in China: A TCS-Sparing Practical Approach |
title_sort | experts’ consensus on the use of pimecrolimus in atopic dermatitis in china: a tcs-sparing practical approach |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021341/ https://www.ncbi.nlm.nih.gov/pubmed/35313362 http://dx.doi.org/10.1007/s13555-022-00696-z |
work_keys_str_mv | AT zhaozuotao expertsconsensusontheuseofpimecrolimusinatopicdermatitisinchinaatcssparingpracticalapproach AT gaoxinghua expertsconsensusontheuseofpimecrolimusinatopicdermatitisinchinaatcssparingpracticalapproach AT liwei expertsconsensusontheuseofpimecrolimusinatopicdermatitisinchinaatcssparingpracticalapproach AT wanghua expertsconsensusontheuseofpimecrolimusinatopicdermatitisinchinaatcssparingpracticalapproach AT liangyunsheng expertsconsensusontheuseofpimecrolimusinatopicdermatitisinchinaatcssparingpracticalapproach AT tangjianping expertsconsensusontheuseofpimecrolimusinatopicdermatitisinchinaatcssparingpracticalapproach AT yaoxu expertsconsensusontheuseofpimecrolimusinatopicdermatitisinchinaatcssparingpracticalapproach AT zhaohua expertsconsensusontheuseofpimecrolimusinatopicdermatitisinchinaatcssparingpracticalapproach AT lugerthomas expertsconsensusontheuseofpimecrolimusinatopicdermatitisinchinaatcssparingpracticalapproach |